Diagnostic and therapeutic challenges in the management of glandular abnormalities of the cervix

Expert Review of Obstetrics and Gynecology

Volumn 7, Issue 1, 2012, Pages 49-58

  Sarian, Luis Otávio ^a,b   Rabelo Santos, Silvia Helena ^c   Derchain, Sophie Françoise Mauricette ^a   Zeferino, Luiz Carlos ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b Federal University of Goáis ^*  (Brazil)

^c FEDERAL UNIVERSITY OF GOIÁS   (Brazil)

Author keywords

adenocarcinoma; cervical cancer; diagnosis; HPV; management; screening; treatment

Indexed keywords

VIRUS DNA;

ADENOCARCINOMA; CANCER GROWTH; CANCER LOCALIZATION; CANCER MORPHOLOGY; CANCER PREVENTION; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; COLPOSCOPY; COMPARATIVE EFFECTIVENESS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; HISTOPATHOLOGY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HYSTERECTOMY; INVASIVE CARCINOMA; NONHUMAN; PAPANICOLAOU TEST; PAPILLOMAVIRUS INFECTION; PROGNOSIS; REVIEW; RISK FACTOR; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CONIZATION; UTERINE CERVIX CYTOLOGY; VIRUS DETECTION;

EID: 83655203015     PISSN: 17474108     EISSN: 17474116     Source Type: Journal    
DOI: 10.1586/eog.11.74     Document Type: Review

References (79)

1. Davey DD, Neal MH, Wilbur DC et al. Bethesda 2001 implementation and reporting rates: 2003 practices of participants in the College of American Pathologists Interlaboratory Comparison Program in Cervicovaginal Cytology. Arch. Pathol. Lab. Med. 128, 1224-1229 (2004). (Pubitemid 39441643)
2. Sharpless KE, Peter F, Schnatz PF et al. Dysplasia associated with atypical glandular cells on cervical cytology. Obstet. Gynecol. 105, 494-500 (2005). (Pubitemid 40271212)
3. Solomon D, Davey D, Kurman R et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 287(16), 2114-2119 (2002). (Pubitemid 34437346)
4. Vizcaino AP, Moreno V, Bosch FX et al. International trends in incidence of cervical cancer: II. Squamous-cell carcinoma. Int. J. Cancer 86, 429-435 (2000). (Pubitemid 30187507)
5. Bulk S, Visser O, Rozendaal L, Verheijen RH, Meijer CJ. Cervical cancer in the Netherlands 1989-1998, decrease of squamous cell carcinoma in older women, increase of adenocarcinoma in younger women. Int. J. Cancer 113, 1005-1009 (2005).
6. Liu S, Semenciw R, Probert A, Mao Y. Cervical cancer in Canada: changing patterns in incidence and mortality. Int. J. Gynecol. Cancer 11, 24-31 (2001). (Pubitemid 32218712)
7. Plaxe SC, Saltzstein SL. Estimation of the duration of the preclinical phase of cervical adenocarcinoma suggests that there is ample opportunity for screening. Gynecol. Oncol. 75, 55-61 (1999). (Pubitemid 29477802)
8. Ruba S, Schoolland M, Allpress S, Sterrett G. Adenocarcinoma in situ of the uterine cervix: screening and diagnostic errors in Papanicolaou smears. Cancer 102, 280-287 (2004). (Pubitemid 39369714)
9. Covell JL, Wilbur DC, Guidos B, Lee KR, Chhieng DC, Mody DR. Epithelial abnormalities: glandular. In: The Bethesda System for Reporting Cervical Cytology: Definitions, Criteria and Explanatory Notes. Solomon D, Nayar R (Eds). Springer-Verlag, NY, USA, 123-156 (2004).
10. Franco EL, Duarte-Franco E, Ferenczy A. Cervical cancer: epidemiology prevention and the role of human papillomavirus infection. CMAJ 164, 1017-1025 (2001). (Pubitemid 34412231)
11. Wright TC Jr, Massad LS, Dunton CJ et al. 2006 consensus guidelines for the management of women with cervical intraepithelial neoplasia or adenocarcinoma in situ. Am. J. Obstet. Gynecol. 197(4), 340-345 (2007). (Pubitemid 47464166)
12. Levine L, Lucci JA 3rd, Dinh TV. Atypical glandular cells: new bethesda terminology and management guidelines. Obstet. Gynecol. Surv. 58, 399-406 (2003). (Pubitemid 36666553)
13. Cangiarella JF, Chhieng DC. Atypical glandular cells - an update. Diagn. Cytopathol. 29, 2 (2003).
14. Castle PE, Fetterman B, Poitras N, Lorey T, Shaber R, Kinney W. Relationship of atypical glandular cell cytology, age, and human papillomavirus detection to cervical and endometrial cancer risks. Obstet. Gynecol. 115(2 Pt 1), 243-248 (2010).
15. Syrjanen K. Is improved detection of adenocarcinoma in situ by screening a key to reducing the incidence of cervical adenocarcinoma? Acta Cytol. 48, 591-594 (2004). (Pubitemid 39287340)
16. Tam KF, Cheung AN, Liu KL et al. A retrospective review on atypical glandular cells of undetermined significance (AGUS) using the Bethesda 2001 classification. Gynecol. Oncol. 91, 603-607 (2003). (Pubitemid 38388158)
17. Westin MC, Derchain SF, Rabelo-Santos SH et al. Atypical glandular cells and adenocarcinoma in situ according to the Bethesda 2001 classification: cytohistological correlation and clinical implications. Eur. J. Obstet. Gynecol. Reprod. Biol. 139, 79-85 (2008). (Pubitemid 351893139)
18. Castellsague X, Diaz M, de Sanjose S et al. Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J. Natl Cancer Inst. 98, 303-315 (2006). (Pubitemid 43338210)
19. Demay RM. The pap smear. In: The Art and the Science of Cytopathology. ASCP Press, Chicago, IL, USA, 61-185 (1996).
20. Mitchell H, Hocking J, Saville M. Improvement in protection against adenocarcinoma of the cervix resulting from participation in cervical screening. Cancer 99, 336-341 (2003). (Pubitemid 38017531)
21. Verdiani LA, Derchain SFM, Schweller M, Gontijo RC, Angelo-Andrade LA, Zeferino LC. Atypical glandular cells in cervical smear: analysis of diagnostic methods. Rev. Bras. Ginecol. Obstet. 25, 193-200 (2003).
22. Derchain SF, Rabelo-Santos SH, Sarian LO et al. Human papillomavirus DNA detection and histological findings in women referred for atypical glandular cells or adenocarcinoma in situ in their Pap smears. Gynecol. Oncol. 95, 618-623 (2004). (Pubitemid 39592530)
23. Liu S, Semenciw R, Probert A, Mao Y. Cervical cancer in Canada: changing patterns in incidence and mortality. Int. J. Gynecol. Cancer 11, 24-31 (2001). (Pubitemid 32218712)
24. Mitchell H, Hocking J, Saville M. Cervical cytology screening history of women diagnosed with adenocarcinoma in situ of the cervix. A case-control study. Acta Cytol. 489, 595-600 (2004). (Pubitemid 39287341)
25. Herzog TJ, Monk BJ. Reducing the burden of glandular carcinomas of the uterine cervix. Am. J. Obstet. Gynecol. 197, 566-571 (2007). (Pubitemid 350166265)
26. Lehtovirta P, Finne P, Nieminen P et al. Prevalence and risk factors of squamous intraepithelial lesions of the cervix among HIV-infected women - a long term follow-up study in a low prevalence population. Int. J. STD AIDS 17, 831-834 (2006). (Pubitemid 46057742)
27. Massad LS, Xie X, Darragh TM et al. Histologic correlates of glandular abnormalities in cervical cytology among women with human immunodeficiency virus. Obstet. Gynecol. 114(5), 1063-1068 (2009).
28. De Sanjose S, Quint WG, Alemany L et al.; Retrospective International Survey and HPV Time Trends Study Group. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 11(11), 1048-1056 (2011).
29. Munoz N, Bosch FX, Castellsague X et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int. J. Cancer 111, 278-285 (2004). (Pubitemid 38924707)
30. Bosch FX, Manos MM, Munoz N et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective: international biological study on cancer (IBSCC) study group. J. Natl Cancer Inst. 87, 796-802 (1995).
31. Andersson S, Rylander E, Larson B et al. Types of human papillomavirus revealed in cervical adenocarcinomas after DNA sequencing. Oncol. Rep. 10, 175-179 (2003).
32. Pirog EC, Kleter B, Olgac S et al. Prevalence of HPV-DNA in different histologic subtypes of cervical adenocarcinoma. Am. J. Pathol. 157, 1055-1062 (2000).
33. Rabelo-Santos SH, Derchain SFM, Villa LL et al. Human papillomavirus-specific genotypes in cervical lesions of women referred for smears with atypical glandular cells or adenocarcinoma in situ. Int. J. Gynecol. Pathol. 28, 272-278 (2009).
34. Zhao C, Chen X, Onisko A, Kanbour A, Austin RM. Follow-up outcomes for a large cohort of US women with negative imaged liquid-based cytology findings and positive high risk human papillomavirus test results. Gynecol. Oncol. 122(2), 291-296 (2011).
35. Burk RD, Masanori T, Gravitt PE et al. Distribution of human papillomavirus types 16 and 18 variants in squamous cell carcinomas and adenocarcinomas of the cervix. Cancer Res. 63, 7215-7220 (2003). (Pubitemid 37413460)
36. De Boer MA, Peters LA, Aziz MF et al. Human papillomavirus type 16 E6, E7, and L1 variants in cervical cancer in Indonesia, Suriname, and The Netherlands. Gynecol. Oncol. 94, 488-494 (2004). (Pubitemid 39024558)
37. Tornesello ML, Duraturo ML, Salatiello I et al. Analysis of human papillomavirus type-16 variants in Italian women with cervical intraepithelial neoplasia and cervical cancer. J. Med. Virol. 74, 117-126 (2004). (Pubitemid 38988868)
38. Berumen J, Ordonez RM, Lazcano E et al. Asian-American variants of human papillomavirus 16 and risk for cervicalcancer: a case-control study. J. Natl Cancer Inst. 93, 1325-1330 (2001). (Pubitemid 32910573)
39. Lizano M, Berumen J, Guido M, Casas L, Garcia-Carranca A. Association between human papillomavirus type 18 variants and histopathology of cervical cancer. J. Natl Cancer Inst. 89, 1227-1231 (1997). (Pubitemid 27350034)
40. De Boer MA, Peters LA, Aziz MF et al. Human papillomavirus type 18 variants: histopathology and E6/E7 polymorphisms in three countries. Int. J. Cancer 114, 422-425 (2005). (Pubitemid 40279963)
41. Villa LL, Sichero L, Rahal P et al. Molecular variants of human papillomavirus types 16 and 18 preferentially associated with cervical neoplasia. J. Gen. Virol. 81, 2959-2968 (2000). (Pubitemid 32000643)
42. Rabelo-Santos SH, Villa LL, Derchain SF et al. variants of human papillomavirus types 16 and 18: histological findings in women referred for atypical glandular cells or adenocarcinoma in situ in cervical smear. Int. J. Gynecol. Pathol. 25, 393-397 (2006). (Pubitemid 44651773)
43. Madeleine MM, Daling JR, Schwartz SM et al. Human papillomavirus and longterm oral contraceptive use increase the risk of adenocarcinoma in situ of the cervix. Cancer Epidemiol. Biomarkers Prev. 10, 171-177 (2001). (Pubitemid 34288526)
44. Widrich T, Kennedy AW, Myers TM, Hart WR, Wirth S. Adenocarcinoma in situ of the uterine cervix: management and outcome. Gynecol. Oncol. 61, 304-308 (1996). (Pubitemid 26169253)
45. Wright TC Jr, Cox JT, Massad LS, Twiggs LB, Wilkinson EJ. 2001 Consensus Guidelines for the management of women with cervical cytological abnormalities. JAMA 287, 2120-2129 (2002). (Pubitemid 34437347)
46. Rabelo-Santos SH, Angelo-Andrade LA, Derchain SF, Oliveira ER, Sarian LO, Westin MC. Endocervical glandular cell abnormalities in conventional cervical smears: cytomorphologic criteria and HPV test for the prediction of glandular neoplasia. Cytopathology 19, 34-43 (2008).
47. Oliveira ER, Derchain SF, Rabelo-Santos SH et al. Detection of high risk human papillomavirus (HPV) DNA by Hybrid Capture II in women referred due to atypical glandular cells in the primary screening. Diagn. Cytopathol. 31(1), 19-22 (2004). (Pubitemid 38857492)
48. Krane JF, Lee KR, Sun D, Yuan L, Crum CP. Atypical glandular cells of undetermined significance. Outcome predictions based on human papillomavirus testing. Am. J. Clin. Pathol. 121, 87-92 (2004). (Pubitemid 38090158)
49. Irvin W, Evans SR, Andersen W et al. The utility of HPV DNA triage in the management of cytological AGC. Am. J. Obstet. Gynecol. 193(2), 559-565 (2005).
50. Ronco G, Giorgi-Rossi P, Carozzi F et al.; New Technologies for Cervical Cancer screening (NTCC) Working Group. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol. 11(3), 249-257 (2010).
51. Sharpless KE, O'Sullivan DM, Schnatz PF. The utility of human papillomavirus testing in the management of atypical glandular cells on cytology. J. Low Genit. Tract. Dis. 13(2), 72-78 (2009).
52. Schnatz PF, Sharpless KE, O'Sullivan DM. Use of human papillomavirus testing in the management of atypical glandular cells. J. Low Genit. Tract. Dis. 13(2), 94-101 (2009).
53. Chen L, Yang B. Assessment of reflex human papillomavirus DNA testing in patients with atypical endocervical cells on cervical cytology. Cancer 114, 236-241 (2008).
54. Castle PE, Fetterman B, Poitras N, Lorey T, Shaber R, Kinney W. Relationship of atypical glandular cell cytology, age, and human papillomavirus detection to cervical and endometrial cancer risks. Obstet. Gynecol. 115(2 Pt 1), 243-248 (2010).
55. Schiffman M, Wentzensen N, Wacholder S, Kinney W, Gage JC, Castle PE. Human papillomavirus testing in the prevention of cervical cancer. J. Natl Cancer Inst. 103(5), 368-383 (2011).
56. Herzog TJ, Monk BJ. Reducing the burden of glandular carcinomas of the uterine cervix. Am. J. Obstetrics Gynecol. 197, 566-571 (2007). (Pubitemid 350166265)
57. Ries L, Harkins D, Krapcho M et al. SEER cancer statistics review, 1975-2004, National Cancer Institute, Bethesda, MD, USA, based on November 2005 SEER data submission (2007).
58. Alfsen GC, Thoresen SO, Kristensen GB, Skovlund E, Abeler VM. Histopathologic subtyping of adenocarcinoma reveals increasing incidence rates of endometrioid tumors in all age groups. Cancer 69, 1291-1299 (2000).
59. Sasieni P, Adams J. Changing rates of adenocarcinoma and adenosquamous carcinoma of the cervix in England. Lancet 357, 1490-1493 (2001). (Pubitemid 32488859)
60. Howlett RI, Marrett LD, Innes MK, Rosen BP, McLachlin CM. Decreasing incidence of cervical adenocarcinoma in Ontario: is this related to improved endocervical Pap test sampling? Int. J. Cancer 120, 362-367 (2006). (Pubitemid 44956847)
61. Sherman ME, Wang SS, Carreon J, Devesa SS. Mortality trends for cervical squamous and adenocarcinoma in the United States: relation to incidence and survival. Cancer 103, 1258-1264 (2005). (Pubitemid 40328098)
62. Eifel PJ, Burke TW, Morris M, Smith TL. Adenocarcinoma as an independent risk factor for disease recurrence in patients with stage IB cervical carcinoma. Gynecol. Oncol. 59, 38-44 (1995).
63. Andersen ES, Nielsen K. Adenocarcinoma in situ of the cervix: a prospective study of conization as definitive treatment. Gynecol. Oncol. 86, 365-369 (2002). (Pubitemid 35425537)
64. Costa S, Negri G, Sideri M et al. Human papillomavirus (HPV) test and PAP smear as predictors of outcome in conservatively treated adenocarcinoma in situ (AIS) of the uterine cervix. Gynecol. Oncol. 106, 170-176 (2007). (Pubitemid 46898589)
65. Kim JH, Park JY, Kim DY, Kim YM, Kim YT, Nam JH. The role of loop electrosurgical excisional procedure in the management of adenocarcinoma in situ of the uterine cervix. Eur. J. Obstet. Gynecol. Reprod. Biol. 145(1), 100-103 (2009).
66. Cohn DE, Morrison CD, Zanagnolo VL, Goist MM, Copeland LJ. Invasive cervical adenocarcinoma immediately following a cone biopsy for adenocarcinoma in situ with negative margins. Gynecol. Oncol. 98, 158-160 (2005). (Pubitemid 40826435)
67. Soutter WP, Haidopoulos D, Gornall RJ et al. Is conservative treatment for adenocarcinoma in situ of the cervix safe? BJOG 108, 1184-1189 (2001). (Pubitemid 33052484)
68. Young JL, Jazaeri AA, Lachance JA et al. Cervical adenocarcinoma in situ: the predictive value of conization margin status. Am. J. Obstet. Gynecol. 197, 195.e1-7; discussion 195.e7-8 (2007).
69. Mestwerdt G. The early diagnosis of cervical carcinomas. Zentralbl Gynakol. 69, 198-202 (1947).
70. Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int. J. Gynaecol. Obstet. 105, 103-104 (2009).
71. Tamimi HK, Figge DC. Adenocarcinoma of the uterine cervix. Gynecol. Oncol. 13, 335-344 (1982). (Pubitemid 12090253)
72. Bisseling KC, Bekkers RL, Rome RM, Quinn MA. Treatment of microinvasive adenocarcinoma of the uterine cervix: a retrospective study and review of theliterature. Gynecol. Oncol. 107, 424-430 (2007). (Pubitemid 350160852)
73. Ceballos KM, Shaw D, Daya D. Microinvasive cervical adenocarcinoma (FIGO stage IA tumors): results of surgical staging and outcome analysis. Am. J. Surg. Pathol. 30, 370-374 (2006). (Pubitemid 43740170)
74. Reynolds EA, Tierney K, Keeney GL et al. Analysis of outcomes of microinvasive adenocarcinoma of the uterine cervix by treatment type. Obstet. Gynecol. 116(5), 1150-1157 (2010).
75. Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. J. Clin. Pathol. 55, 244-265 (2002). (Pubitemid 34293391)
76. Jaworski RC, Pacey NF, Greenberg ML, Osborn RA. The histologic diagnosis of adenocarcinoma in situ and related lesions of the cervix uteri: adenocarcinoma in situ. Cancer 61, 1171-1181 (1988). (Pubitemid 18078608)
77. Zaino RJ. Symposium part I: adenocarcinoma in situ, glandular dysplasia, and early invasive adenocarcinoma of the uterine cervix. Int. J. Gynecol. Pathol. 21, 314-326 (2002).
78. Baalbergen A, Ewing-Graham PC, Hop WCJ, Struijk P, Helmerhorst TJM. Prognostic factors in adenocarcinoma of the uterine cervix. Gynecol. Oncol. 92, 262-267 (2004). (Pubitemid 38147402)
79. Shimada M, Kiwaga J, Nishimura R et al. Ovarian metastasis in carcinoma of the uterine cervix. Gynecol. Oncol. 101, 234-237 (2006).